Werewolf Therapeutics, INC Form 4 insider transactions

Ansbert Gadicke, a director and 10% owner of Werewolf Therapeutics, along with affiliated entities, reported the sale of 141,927 shares of common stock in late 2025.

Luke Evnin, a director at Werewolf Therapeutics, Inc., reported the sale of 125,576 shares of common stock through pre-arranged 10b5-1 plans.

MPM BioVentures, a 10% owner and director, reported the sale of 195,666 shares of Werewolf Therapeutics common stock through pre-scheduled 10b5-1 plans.

Ansbert Gadicke, a director and 10% owner of Werewolf Therapeutics, along with affiliated entities, has filed a Form 4 detailing planned sales of 195,666 shares of common stock in late November 2025 under a Rule 10b5-1 plan.

Werewolf Therapeutics Director Luke Evnin reported the sale of over 100,000 common shares through pre-arranged 10b5-1 plans.

MPM BioVentures, a 10% owner and director, reported selling over 160,000 shares of Werewolf Therapeutics common stock in pre-planned transactions.

A 10% owner and director of Werewolf Therapeutics, Ansbert Gadicke and related entities, reported the sale of over 160,000 common shares in mid-November 2025 under a pre-established trading plan.

Luke Evnin, a director at Werewolf Therapeutics, Inc., reported the sale of 134,553 shares of common stock across three transactions in mid-November 2025, executed under a pre-arranged 10b5-1 plan.

MPM BioVentures, a 10% owner and director, reported multiple sales of Werewolf Therapeutics common stock totaling 209,652 shares in mid-November 2025.

Ansbert Gadicke and affiliated entities reported the sale of Werewolf Therapeutics common stock totaling 209,652 shares over three days in November 2025.

Luke Evnin, a director at Werewolf Therapeutics, sold 137,041 shares of common stock across four transactions in November 2025, pursuant to a pre-established 10b5-1 plan.

MPM BioVentures, a 10% owner and director, reported the sale of over 213,000 shares of Werewolf Therapeutics common stock through a pre-arranged 10b5-1 plan.

A 10% owner and director of Werewolf Therapeutics, Inc. reported the sale of over 213,000 shares of common stock through pre-arranged trading plans.

Luke Evnin, a director at Werewolf Therapeutics, Inc., reported the sale of 155,885 common shares over three days in early November 2025, executed under a pre-arranged 10b5-1 trading plan.

MPM BioVentures entities, a 10% owner and director of Werewolf Therapeutics, reported the sale of 242,890 common shares over three days in early November 2025, pursuant to a Rule 10b5-1 plan.

Ansbert Gadicke and affiliated entities divested over 240,000 shares of Werewolf Therapeutics common stock in early November 2025 under a Rule 10b5-1 trading plan.

Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc., sold a total of 189,356 shares of common stock across three transactions in late October and early November 2025 through a pre-arranged 10b5-1 plan.

MPM BioVentures, a 10% owner and director of Werewolf Therapeutics, Inc., reported selling 295,043 shares of common stock across three transactions in late October and early November 2025.

Ansbert Gadicke, a Director and 10% owner of Werewolf Therapeutics, Inc., reported multiple sales of common stock totaling 295,043 shares in late October and early November 2025.

Werewolf Therapeutics Director Luke Evnin sold 177,145 shares of common stock over three days in late October 2025, pursuant to a pre-arranged 10b5-1 plan.

MPM BioVentures 2014 L.P. and affiliated entities reported multiple sales of Werewolf Therapeutics common stock totaling 276,017 shares under a pre-arranged 10b5-1 plan.

Ansbert Gadicke, a Director and 10% owner of Werewolf Therapeutics, Inc., along with affiliated entities, reported the sale of 276,017 shares of common stock over three days in late October 2025.

Werewolf Therapeutics, Inc. Director Alon Lazarus was granted 27,000 stock options with an exercise price of $1.29 per share, vesting over one year or by the next annual meeting.

Werewolf Therapeutics, Inc. Director Morrison Briggs was granted 27,000 stock options with an exercise price of $1.29, vesting on the earlier of the first anniversary of the grant date or the next annual meeting.

Werewolf Therapeutics, Inc. Director Meeta Chatterjee was granted 27,000 stock options with an exercise price of $1.29 per share, vesting over one year or until the next annual meeting.

Luke Evnin, a Director at Werewolf Therapeutics, Inc., was granted 27,000 stock options with an exercise price of $1.29, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Michael A. Sherman, a Director at Werewolf Therapeutics, Inc., was granted 27,000 stock options with an exercise price of $1.29, aligning his incentives with long-term shareholder value.

Werewolf Therapeutics, Inc. Director Anil K. Singhal was granted stock options for 17,358 shares of common stock, including options previously delayed due to a clerical error, as disclosed in a recent SEC Form 4 filing.

Werewolf Therapeutics, Inc. director Michael B. Atkins was granted 27,000 stock options with an exercise price of $1.29, vesting over one year or until the next annual meeting.

RA Capital Management, a significant shareholder in Werewolf Therapeutics, has increased its holdings through a series of open market purchases between May 12 and May 14, 2025.